

Claims:

1. A compound which is N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide having the structure:



or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 which is N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide having the structure:



.

3. A pharmaceutical composition, comprising a compound according to any one of claims 1-2 or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

4. A compound according to any one of claims 1-2 or a pharmaceutically acceptable salt thereof for use in treating a BRAF-associated tumor in a subject in need thereof.

5. The compound for use according to claim 4, wherein said BRAF-associated tumor has a BRAF Class II mutation.

6. The compound for use according to claim 5, wherein said BRAF Class II mutation is a BRAF non-V600 mutation.

7. The compound for use according to any one of claims 4-6, wherein said BRAF-associated tumor is a cancer selected from lung cancer, melanoma, colorectal cancer, breast cancer, pancreatic cancer, thyroid cancer, prostate cancer, adenoid cystic carcinoma, appendiceal cancer, small intestine cancer, head and neck squamous cell carcinoma, angiosarcoma, bladder carcinoma, plasma cell neoplasm, hepato-pancreato-biliary carcinoma, ovary carcinoma, neuroendocrine cancer, cholangiocarcinoma and CNS cancers.

8. The compound for use according to any one of claims 4-7, wherein said BRAF-associated tumor is a primary brain tumor.

9. The compound for use according to any one of claims 4-8, wherein said compound is used with an additional anticancer therapy.

10. The compound for use of claim 9, wherein the additional anticancer therapy is an anticancer agent.

11. The compound for use of claim 10, wherein the additional anticancer agent is selected from MEK inhibitors, BRAF inhibitors, EGFR inhibitors, inhibitors of HER2 and/or HER3, Axl inhibitors, PI3K inhibitors, SOS1 inhibitors, signal transduction pathway inhibitors, checkpoint inhibitors, modulators of the apoptosis pathway, cytotoxic chemotherapeutics, angiogenesis-targeted therapies, and immune-targeted agents.

12. The compound for use of claim 11, wherein the additional anticancer agent is a MEK inhibitor.

13. The compound for use of claim 12, wherein the MEK inhibitor is binimetinib or a pharmaceutically acceptable salt thereof.

14. The compound for use of claim 11, wherein the additional anticancer agent is an EGFR inhibitor.

15. The compound for use of claim 14, wherein the EGFR inhibitor is cetuximab.